Incyte (INCY) is Initiated by Raymond James to Mkt Perform , according to the research report released to the investors. The shares recommendation by the Brokerage Firm was released on Jan-5-2016.
Incyte Corporation has dropped 8.04% during the last 3-month period . Year-to-Date the stock performance stands at 48.34%.
Incyte Corporation (NASDAQ:INCY) has lost 0.43% during the past week and dropped 0.6% in the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 0.4% and the outperformance increases to 1.72% for the last 4 weeks.
Shares of Incyte Corporation (NASDAQ:INCY) ended Thursday session in red amid volatile trading. The shares closed down 0.66 points or 0.6% at $108.45 with 872,220 shares getting traded. Post opening the session at $108.24, the shares hit an intraday low of $108.24 and an intraday high of $109.92 and the price vacillated in this range throughout the day. The company has a market cap of $20,172 million and the number of outstanding shares have been calculated to be 186,001,820 shares. The 52-week high of Incyte Corporation (NASDAQ:INCY) is $133.62 and the 52-week low is $69.05.
Currently the company Insiders own 13.2% of Incyte Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -3.55% . Institutional Investors own 92.33% of Incyte Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -11.73%. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange,The officer (EVP, General Counsel) of Incyte Corp, Siegel Eric H. sold 1,936 shares at $107.96 on December 10, 2015. The Insider selling transaction had a total value worth of $209,011. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received worldwide development and commercialization rights for the compound for inflammatory and autoimmune diseases. The JAK family is composed of four tyrosine kinases JAK1, JAK2, JAK3 and Tyk2 that are involved in the signaling of a number of cytokines and growth factors.